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Abstract 
Introduction: Insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) have 
been associated with increased risk of breast cancer. Methods: We report our findings on the 
effects of 16 weeks of aerobic exercise on IGF axis proteins, insulin, glucose and insulin 
resistance of 319 young sedentary women. Demographics, health surveys, body composition, 
dietary intake and blood samples were collected at baseline and 16 weeks. IGF-1 and IGF 
binding proteins 1, 2, and 3 were measured by ELISA’s. Results: Exercise adherence was 88% 
and the dropout rates for the exercise and control groups were 21.7% and 14.5%, respectively. 
There was a small significant change from baseline in IGFBP-3 concentrations. IGFBP-3 levels 
decreased in controls and increased in exercisers. The between group difference was 
significant. No other changes were noted. Conclusion: Sixteen weeks of exercise had 
minimum or no effect on IGF proteins of young women. Impact: Our study supports findings 
from previous studies conducted in older populations and raises the question of what type of 
intervention is needed to change circulating levels of IGF proteins in humans. 
 
  
Introduction 
Insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) have been associated 
with increased risk of premenopausal breast cancer (1). Recently, results from a pooled data 
analysis of 17 prospective studies revealed that IGF-1 levels were positively associated with 
estrogen receptor positive breast cancer, regardless of menopausal status (2). It is unclear 
whether exercise training affects circulating levels of IGF-1 and binding proteins. Previous 
exercise trials in postmenopausal women have reported mixed results (3-5). In young women, 
although strength training has been found to decrease IGF-1 and insulin levels (6), there is a 
lack of large longitudinal studies examining the effects of aerobic exercise on IGF proteins. We 
conducted a randomized clinical trial to examine the effects of exercise training on insulin, 
glucose, and IGF axis proteins in sedentary young women. We hypothesized that exercise 
training would lower IGF-1, insulin, glucose and the molar ratio of IGF-1/IGFBP-3 and increase 
binding protein levels in the direction associated with decreased breast cancer risk. 
 
Methods 
The Women in Steady Exerciser Research (WISER) study was a randomized clinical trial 
comparing the effects of a 16-week aerobic exercise intervention versus no exercise on markers 
associated with breast cancer risk (7). The study was approved by the University of Minnesota 
Human Subjects Review Committee. Participants were healthy women aged 18-30 years, with a 
BMI between 18.5-40 kg/m2, sedentary, not taking hormonal contraceptives, and not dieting. 
Women were randomly assigned to the exercise intervention (n = 166) or the control group (n = 
153). 
The exercise intervention consisted of 30 minutes of weight-bearing aerobic exercise, 
five times per week, at a specified intensity based on age-predicted heart rate maximum 
(HRmax). Exercise intensity increased every four weeks to reach 80-85% of HRmax. The 
control group was asked to maintain their usual levels of physical activity.   
At baseline and 16-weeks the following were collected: demographic information, 
anthropometrics, body composition via DXA (Lunar Radiation Corp., Madison, WI), dietary 
intake via 3-day food records, health habits, fitness level via sub-maximal tests, and blood 
samples, which were collected in the morning during the follicular phase of participants’ cycles. 
Fasting glucose and insulin levels were measured at the Fairview University Diagnostic 
Laboratories (Minneapolis, MN). IGF proteins were measured by ELISAs (DSL, Webster, 
TX).  Intra- and inter-assay coefficients of variation for IGF-1, IGFBP-1, IGFPB-2, and IGFBP-3 
were 1.8%, 1.9%, 2.2%, and 1.3% and 7.2%, 9.3%, 10.6%, and 4.9%, respectively. All samples 
from the same participant were analyzed in the same batch. 
Unadjusted comparisons of demographic characteristics were performed by t-tests and 
chi-squares for continuous and categorical variables, respectively. Comparisons between 
groups were adjusted for age and BMI strata with a general linear model. This was an intent-to-
treat analysis. Insulin and IGFBP-1 were analyzed on the log scale; changes in outcome 
variables were analyzed on the original scale. We had 80% power to detect a difference in 
change from baseline to 16 weeks between exercisers and controls of 20.7 ng/L for IGF-1, 1.29 
mU/L for insulin, 0.146 mmols/L for glucose and 4.97, 51.4, and 161 ng/mL for IGFBP-1, -2, and 
-3, respectively. All analyses were performed with SAS software (version 9.2, SAS Institute, 
Cary, NC). 
 
Results 
We randomized 391 participants into the study and 319 successfully completed the study. The 
dropout rates for the exercise and control groups were 21.7% and 14.5%, respectively. Three 
participants (two controls and one exerciser) were excluded from analysis because of unusually 
high follow-up insulin levels (i.e., more than a 5-fold increase from baseline).  
There were no baseline differences in demographic characteristics and other variables 
between groups (Table 1). Fitness increased by 0.91 METs in the exercisers compared to 0.14 
METs in controls (p < 0.0001). Exercisers completed an average 92% of assigned minutes of 
exercise, and 140 women (86%) exercised for at least 14 weeks. 
IGFBP-3 levels decreased in controls and increased in exercisers with the difference in 
change between groups being significant (Table 2). There were no differences between groups 
in the other outcomes.  
 
Discussion 
This randomized trial suggests that 16 weeks of aerobic exercise, 30 minutes/day, 5 days/ 
week, has minimal or no effect on levels of insulin, glucose, IGF-1 and IGF binding proteins 
among young, healthy eumenorrheic women. The WISER study strengths include the type of 
exercise intervention chosen, which was based on current public health guidelines, and the 
excellent retention and adherence rates. Furthermore, previous studies examining the effects of 
exercise on IGF axis proteins have focused on postmenopausal women and found mixed 
results (3-4). The WISER study is the first large trial to assess the effects of aerobic exercise on 
IGF axis proteins in young women. Though we found minimal effects, it may be that longer 
exercise interventions or alternative approaches to the current physical activity interventions are 
needed to change the levels of these markers in young women. 
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Table 1. Baseline characteristics of controls and exercisers*.
Controls Exercisers
(n = 151) (n  = 165) 
Age (years ) 25.3 ± 3.5 25.4 ± 3.4 0.8
Body Fat (%) 36.2 ± 8.3 36.3 ± 8.7 0.86
Weight (kg) 67.7 ± 14.7 67.4 ± 14.6 0.86
Fitness (METS) 7.0 ± 1.5 6.9 ± 1.5 0.59
Ethnicity 
    Hispanic 6 (4.0) 8 (4.8) 0.7
    Non-hispanic 145 (96.0) 157 (95.2) 
Race 
    American Indian 0 1 (0.6) 0.59
    Asian/Pacific Islander 26 (17.2) 20 (12.1) 
    Black 11 (7.3) 13 (7.9) 
    White 106 (70.2) 124 (75.1) 
    Other/multi-race 8 (5.3) 7 (4.2) 
Education 
    Less than college 49 (32.5) 53 (32.0) 0.27
    College degree 63 (41.7) 56 (34.0) 
    Graduate/professional degree 39 (25.8) 56 (34.0) 
Marital Status 
    Never married 122 (80.8) 137 (83.0) 0.62
    Married/partnered 26 (17.2) 25 (15.2) 
    Divorced/separated 3 (2.0) 3 (1.8) 
BMI 
    ≤ 25 kg/m2 99 (65.5) 101 (61.2) 0.2
    25-30 kg/m2 30 (19.9) 46 (27.9) 
    ≥ 30 kg/m2 22 (14.6) 18 (10.9) 
p
*Values are presented as mean ± SD for continuous variables or n (%) for
categorical variables.
Table 2. Changes in glucose, insulin, insulin resistance and IGF proteins for controls versus exercisersa.
Baseline 4 months Change at 4 months
% Change at 4 
months
Glucose (mmols/L) 
   Control (n = 151) 4.44 ± 0.03 4.40 ± 0.03 -0.76 ± 0.7 -0.50 ± 0.9
   Exercise (n = 165) 4.52 ± 0.03 4.50 ± 0.03 -0.39 ± 0.7 0.08 ± 0.8
   p-value 0.12 0.04 0.696 0.63
Insulin  (mU/L)            
   Control (n = 151) 6.22 (5.7 – 6.8) 6.31 (5.8 – 6.9) 0.10 ± 0.3 19.0 ± 5.6* 
   Exercise (n = 165)  6.14 (5.6 – 6.7) 5.82 (5.3 – 6.3) -0.51 ± 0.3 8.2 ± 5.4 
   p-value 0.835 0.194 0.186 0.158
HOMA index
   Control (n = 151) 1.49 ± 0.08 1.49 ± 0.07 0.00 ± 0.07 20.6 ± 6.2 
   Exercise (n = 165) 1.48 ± 0.07 1.37 ± 0.06 -0.12 ± 0.07 9.5 ± 5.9 
   p-value 0.954 0.229 0.236 0.186
QUICKI
   Control (n = 151) 0.393 ± 0.0 0.375 ± 0.0 -0.02 ± 0.0* -4.50 ± 0.8* 
   Exercise (n = 165) 0.391 ± 0.0 0.378 ± 0.0 -0.01 ± 0.0* -3.30 ± 0.7* 
   p-value 0.158 0.455 0.247 0.254
IGF-1  (ng/mL) 
   Control (n = 151) 394.7 ± 7.8 382.1 ± 7.8 -11.1 ± 5.5 -1.63 ± 1.5 
   Exercise (n = 165) 386.0 ± 7.4 377.3 ± 7.3 -9.8 ± 5.2 -0.84 ± 1.4 
   p-value 0.417 0.652 0.867 0.695
IGFBP-1  (ng/mL) 
   Control (n = 151) 21.1 (18.9 – 23.6) 20.5 (18.1 – 23.1) -0.25 ± 1.3 15.4 ± 7.1* 
   Exercise (n = 165) 24.5 (22.0 – 27.2) 22.9 (20.4 – 25.6) -0.90 ± 1.3 12.2 ± 6.8 
   p-value 0.059 0.181 0.712 0.742
IGFBP-2  (ng/mL) 
   Control (n = 151) 347.6 ± 20.6 408.0 ± 21.5 52.2 ± 14.8 37.4 ± 24.5* 
   Exercise (n = 165) 370.6 ± 19.4 414.3 ± 20.3 37.4 ± 14.4 51.8 ± 23.8* 
   p-value 0.413 0.828 0.412 0.638
IGFBP-3  (ng/mL) 
   Control (n = 151)     4942.1 ± 69.4 4837.1 ± 68.7 -103.1 ± 42.6 -1.49 ± 0.9 
   Exercise (n = 165) 4863.6 ± 65.5 4883.9 ± 64.8 18.7 ± 40.7 0.99 ± 0.9 
   p-value 0.407 0.617 0.035 0.051
IGF-1:IGFBP-3†
   Control (n = 151) 0.29 ± 0.00 0.28 ± 0.00 -0.317 ± 0.3 -0.45 ± 1.1 
   Exercise (n = 165) 0.29 ± 0.00 0.28 ± 0.00 -0.817 ± 0.3 -1.85 ± 1.0 
   p-value 0.959 0.543 0.22 0.334
*Significant change from baseline within treatment group at p<.05.
†Values for change at 4 months were multiplied by 100 to facilitate presentation.
aValues are expressed either as mean ±SE  or geometric mean (lower CI – upper CI)  for 
baseline data and as mean ±SE  for changes.
